Physician profile
Anupkumar Shetty
NPI 1275504136
$4,369.74
in general payments reported to CMS, 2019-2025
25 companies · $249 in 2025
The $249 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $496 · 2021: $569 · 2022: $1,361 · 2023: $840 · 2024: $663 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,004.86 | 2020-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $633.70 | 2022-2025 | |
| Amgen INC. | $278.23 | 2024-2025 | Tavneos, Krystexxa |
| Horizon Therapeutics Plc | $231.35 | 2022-2023 | Krystexxa |
| Travere Therapeutics, INC. | $185.98 | 2022-2024 | |
| Glaxosmithkline, LLC. | $175.09 | 2021-2024 | Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $173.20 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $138.51 | 2019 | |
| Fresenius USA Marketing, INC. | $120.32 | 2022-2024 | Nxstage System One, Velphoro |
| Aurinia Pharma U.S., INC. | $109.23 | 2021-2025 | Lupkynis |
| Nxstage Medical, INC. | $63.50 | 2022-2023 | Nxstage System One |
| Baxter Healthcare | $49.93 | 2023-2024 | Renal - Acute, Gambro - Accute |
| Otsuka America Pharmaceutical, INC. | $42.79 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $27.44 | 2025 | Prevymis |
| Alnylam Pharmaceuticals INC. | $23.52 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.46 | 2024 | |
| Genentech USA, INC. | $20.89 | 2019 | |
| Novo Nordisk INC | $19.16 | 2023 | Ozempic, Rybelsus |
| Eisai INC. | $18.16 | 2019 | |
| Shield Therapeutics INC | $15.62 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.80 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupkumar Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.